下载本文档
版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemE1-AminobenzotriazoleCat. No.: HY-103389CAS No.: 1614-12-6Synonyms: ABT; 3-Aminobenzotriazole分式: CHN分量: 134.14作靶点: Cytochrome P450作通路: Metabolic Enzyme/Protease储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 mont
2、h溶解性数据体外实验 DMSO : 125 mg/mL (931.86 mM; Need ultrasonic)H2O : 50 mg/mL (372.74 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 7.4549 mL 37.2745 mL 74.5490 mL5 mM 1.4910 mL 7.4549 mL 14.9098 mL10 mM 0.7455 mL 3.7274 mL 7.4549 mL请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液,并请注意储备液的保存式和期限。体内实验请
3、根据您的实验动物和给药式选择适当的溶解案,配制前请先配制澄清的储备液,再依次添加助溶剂(为保证实验结果的可靠性,体内实验的作液,建议您现现配,当天使;澄清的储备液可以根据储存条件,适当保存;以下溶剂前的百分 指该溶剂在您配制终溶液中的体积占):1. 请依序添加每种溶剂: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.08 mg/mL (15.51 mM); Clear solution2. 请依序添加每种溶剂: 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.08 mg/mL (
4、15.51 mM); Clear solution1/3 Master of Small Molecules 您边的抑制剂师www.MedChemE3. 请依序添加每种溶剂: 10% DMSO 90% corn oilSolubility: 2.08 mg/mL (15.51 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 1-Aminobenzotriazole细胞素 P450 (P450) 的特异且不可逆抑制剂。IC50 & Target P450 1体外研究 1-Aminobenzotriazole (ABT) alone significantly
5、increases the expression levels of CYP2B6 in two differenthepatocytes (7.3- and 10.8-fold, respectively). Upon co-treatment with 1-Aminobenzotriazole, the induction ofCYP2B6 expression by CITCO or rifampin is potentiated: 12.6- and 4.0-fold for CITCO as well as 3.9- and2.5-fold for rifampin. 1-Amino
6、benzotriazole has a greater potentiation effect on CITCO than on rifampin. 1-Aminobenzotriazole alone increases the expression levels of CYP3A4 in tow different hepatocytes (by 2.0-and 3.8-fold). Upon co-treatment with 1-Aminobenzotriazole, the effects of CITCO on CYP3A4 expressionlevels are potenti
7、ated by 3.8- and 6.0- fold as compare to cells treated with CITCO alone 1. 1-Aminobenzotriazole (ABT) (1 mM) shows pronounced (95%) inhibition of the formation of N-acetylprocainamide compare with the control without 1-Aminobenzotriazole 2.体内研究 Oral 1-Aminobenzotriazole (ABT) (100 mg/kg, 2 h predose
8、) decreases the clearance of intravenousprocainamide (45%) in rats, accompanied by a decreased N-acetylprocainamide-to-procainamide ratio inurine (0.74 versus 0.21) and plasma (area under the curve ratio 0.59 versus 0.11). The urinary recovery ofprocainamide increases from 18 to 30%, whereas the rec
9、overy of N-acetylprocainamide in urine decreasesfrom 13.3 to 6.5% with 1-Aminobenzotriazole 2. Pretreatment of rats with 100 mg/kg oral 1-Aminobenzotriazole (ABT) administered 2 hours before a semisolid caloric test meal markedly delays gastricemptying. 1-Aminobenzotriazole also increases stomach we
10、ights by 2-fold 3.PROTOCOLCell Assay 1 Freshly isolated human hepatocytes are used in this study. Briefly, hepatocytes are placed in serum-freeWilliams E media containing 0.1 M dexamethasone, 10 g/mL gentamicin, 15 mM HEPES, 2 mM L-glutamine, and 1% ITS. Cells are incubated for 10 hr at 37C in an at
11、mosphere containing 5% CO2. Afterrecovery, the hepatocytes are treated with media containing CITCO (100 nM), rifampin (10 M) or vehicle(ethanol), with or without 1-Aminobenzotriazole (ABT) (1 mM) for 72 hr 1.MCE has not independently confirmed the accuracy of these methods. They are for reference on
12、ly.Animal Male Sprague-Dawley rats (0.26 to 0.30 kg, n=3 per treatment) receive an oral dose of 1-AminobenzotriazoleAdministration 2 (ABT) (100 mg/kg, 2 mL/kg) 2 h before a single intravenous bolus of procainamide (10 mg/kg, 2 mL/kg). Thecontrol group receives only the intravenous bolus of procainam
13、ide without 1-Aminobenzotriazolepretreatment. The vehicle for both 1-Aminobenzotriazole and procainamide is 10% dimethylacetamide/90%water (v/v). Rats are fed 4 h after dosing, and serial blood samples are collected at 0.03, 0.17, 0.25, 0.5, 1, 2,4, and 6 h postdose. Blood samples are centrifuged us
14、ing tubes containing K3-EDTA as the anticoagulant to2/3 Master of Small Molecules 您边的抑制剂师www.MedChemEobtain plasma. Urine samples are also collected over 24 h postdose. Plasma and urine samples are frozen at-20C until analysis 2.MCE has not independently confirmed the accuracy of these methods. They
15、 are for reference only.REFERENCES1. Yang K, et al. Induction of CYP2B6 and CYP3A4 expression by 1-aminobenzotriazole (ABT) in human hepatocytes. Drug Metab Lett.2010 Aug;4(3):129-33.2. Sun Q, et al. 1-Aminobenzotriazole, a known cytochrome P450 inhibitor, is a substrate and inhibitor of N-acetyltransferase. Drug MetabDispos. 2011 Sep;39(9):1674-9.3. Stringer RA, et al. 1-Aminobenzotriazole modulates oral drug pharmacokinetics through cytochrome P450 inhibition and delay of gastricemptying in rats. Drug Me
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 餐饮服务承揽合同三篇
- 管道行业安全管理工作心得
- 2025年全球及中国丙二醛行业头部企业市场占有率及排名调研报告
- 2025年全球及中国头发护理用神经酰胺行业头部企业市场占有率及排名调研报告
- 2025年全球及中国DHA微囊粉行业头部企业市场占有率及排名调研报告
- 2025年全球及中国三维足底扫描系统行业头部企业市场占有率及排名调研报告
- 2025-2030全球电动跨式堆垛机行业调研及趋势分析报告
- 2025年全球及中国介孔二氧化硅微球行业头部企业市场占有率及排名调研报告
- 2025年全球及中国多相真空萃取机行业头部企业市场占有率及排名调研报告
- 2025-2030全球豆荚酒店行业调研及趋势分析报告
- 《社区康复》课件-第一章 总论
- 上海中考英语考纲词汇
- 【工商管理专业毕业综合训练报告2600字(论文)】
- 《幼儿园健康》课件精1
- 22S803 圆形钢筋混凝土蓄水池
- 2023年开心英语四年级上册全册练习
- Hadoop大数据开发实例教程高职PPT完整全套教学课件
- 企业中层管理人员测评问题
- 人教版高中地理必修一全册测试题(16份含答案)
- 《民航服务沟通技巧》教案第11课孕妇旅客服务沟通
- 新东方四级词汇-正序版
评论
0/150
提交评论